Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Prinssen, Eric P.M
Koek, Wouter
and
Kleven, Mark S
2000.
Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: a role for tonic activation of 5-HT1A receptors.
European Journal of Pharmacology,
Vol. 395,
Issue. 2,
p.
143.
Prinssen, E.P.M.
Koek, W.
Colpaert, F.C.
and
Kleven, M.S.
2000.
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Behavioural Pharmacology,
Vol. 11,
Issue. 3 & 4,
p.
299.
Deshpande, Laxmikant S.
Khisti, Rahul T.
and
Chopde, Chandrabhan T.
2001.
Cataleptic effect of neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice: modulation by serotonergic agents.
Brain Research,
Vol. 898,
Issue. 1,
p.
13.
Miyata, Shinji
Hamamura, Takashi
Yoshinaga, Junji
Nakamura, Yasushi
Imamura, Takaki
Hikiji, Akiyoshi
and
Kuroda, Shigetoshi
2001.
Amelioration of Frozen Gait by Tandospirone, a Serotonin 1A Agonist, in a Patient with Pure Akinesia Developing Resistance to L-threo-3,4-dihydroxyphenylserine.
Clinical Neuropharmacology,
Vol. 24,
Issue. 4,
p.
232.
Depoortere, Ronan
Boulay, Denis
Perrault, Ghislaine
Bergis, Olivier
Decobert, Michel
Françon, Dominique
Jung, Mireille
Simiand, Jacques
Soubrié, Philippe
and
Scatton, Bernard
2003.
SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity.
Neuropsychopharmacology,
Vol. 28,
Issue. 11,
p.
1889.
Chu, Wenhua
Tu, Zhude
McElveen, Elizabeth
Xu, Jinbin
Taylor, Michelle
Luedtke, Robert R.
and
Mach, Robert H.
2005.
Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands.
Bioorganic & Medicinal Chemistry,
Vol. 13,
Issue. 1,
p.
77.
Bantick, R. Alexander
De Vries, Michiel H.
and
Grasby, Paul M.
2005.
The effect of a 5-HT1A receptor agonist on striatal dopamine release.
Synapse,
Vol. 57,
Issue. 2,
p.
67.
Assié, Marie-Bernadette
Dominguez, Hélène
Consul-Denjean, Nathalie
and
Newman-Tancredi, Adrian
2006.
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Naunyn-Schmiedeberg's Archives of Pharmacology,
Vol. 373,
Issue. 6,
p.
441.
Zazpe, Arturo
Artaiz, Inés
Innerárity, Ana
del Olmo, Elena
Castro, Elena
Labeaga, Luis
Pazos, Angel
and
Orjales, Aurelio
2006.
In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Neuropharmacology,
Vol. 51,
Issue. 1,
p.
129.
Bardin, Laurent
Kleven, Mark S
Barret-Grévoz, Catherine
Depoortère, Ronan
and
Newman-Tancredi, Adrian
2006.
Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist Properties.
Neuropsychopharmacology,
Vol. 31,
Issue. 9,
p.
1869.
McCreary, Andrew C
Glennon, Jeffrey C
Ashby, Charles R
Meltzer, Herbert Y
Li, Zhu
Reinders, Jan-Hendrik
Hesselink, Mayke B
Long, Stephen K
Herremans, Arnoud H
van Stuivenberg, Herman
Feenstra, Rolf W
and
Kruse, Chris G
2007.
SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug.
Neuropsychopharmacology,
Vol. 32,
Issue. 1,
p.
78.
Auclair, Agnès L.
Galinier, Alexandra
Besnard, Joël
Newman-Tancredi, Adrian
and
Depoortère, Ronan
2007.
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats.
Psychopharmacology,
Vol. 193,
Issue. 1,
p.
45.
Bardin, Laurent
Auclair, Agnès
Kleven, Mark S.
Prinssen, Eric P.M.
Koek, Wouter
Newman-Tancredi, Adrian
and
Depoortère, Ronan
2007.
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Behavioural Pharmacology,
Vol. 18,
Issue. 2,
p.
103.
Depoortère, R
Bardin, L
Auclair, A L
Kleven, M S
Prinssen, E
Colpaert, F
Vacher, B
and
Newman‐Tancredi, A
2007.
F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia.
British Journal of Pharmacology,
Vol. 151,
Issue. 2,
p.
253.
Butini, Stefania
Gemma, Sandra
Campiani, Giuseppe
Franceschini, Silvia
Trotta, Francesco
Borriello, Marianna
Ceres, Nicoletta
Ros, Sindu
Coccone, Salvatore Sanna
Bernetti, Matteo
De Angelis, Meri
Brindisi, Margherita
Nacci, Vito
Fiorini, Isabella
Novellino, Ettore
Cagnotto, Alfredo
Mennini, Tiziana
Sandager-Nielsen, Karin
Andreasen, Jesper Tobias
Scheel-Kruger, Jorgen
Mikkelsen, Jens D.
and
Fattorusso, Caterina
2009.
Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior.
Journal of Medicinal Chemistry,
Vol. 52,
Issue. 1,
p.
151.
Ellenbroek, Bart A.
2012.
Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?.
Neuropharmacology,
Vol. 62,
Issue. 3,
p.
1371.
Cappelli, Andrea
Manini, Monica
Valenti, Salvatore
Castriconi, Federica
Giuliani, Germano
Anzini, Maurizio
Brogi, Simone
Butini, Stefania
Gemma, Sandra
Campiani, Giuseppe
Giorgi, Gianluca
Mennuni, Laura
Lanza, Marco
Giordani, Antonio
Caselli, Gianfranco
Letari, Ornella
and
Makovec, Francesco
2013.
Synthesis and structure–activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.
European Journal of Medicinal Chemistry,
Vol. 63,
Issue. ,
p.
85.
Huang, Xuefei
Yang, Jing
Yang, Sijin
Cao, Shousong
Qin, Dalian
Zhou, Ya
Li, Xiaoli
Ye, Yun
and
Wu, Jianming
2017.
Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms.
Oncotarget,
Vol. 8,
Issue. 60,
p.
102705.
Meadows, Samantha M.
Chambers, Nicole E.
Conti, Melissa M.
Bossert, Sharon C.
Tasber, Crystal
Sheena, Eitan
Varney, Mark
Newman-Tancredi, Adrian
and
Bishop, Christopher
2017.
Characterizing the differential roles of striatal 5-HT 1A auto- and hetero-receptors in the reduction of l -DOPA-induced dyskinesia.
Experimental Neurology,
Vol. 292,
Issue. ,
p.
168.
Lanza, Kathryn
and
Bishop, Christopher
2018.
Serotonergic targets for the treatment of l-DOPA-induced dyskinesia.
Journal of Neural Transmission,
Vol. 125,
Issue. 8,
p.
1203.
Comments
No Comments have been published for this article.